Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

ITP - ifosfamide, paclitaxel, and cisplatin; EP – etoposide/platinum; IA-EP – ifosfamide/Adriamycin-EP; Gem-FLP – gemcitabine, 5-FU, leucovorin, cisplatin. This is an ASCO Meeting Abstract from the ...

Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic ...

Cade, Telix Group Chief Medical Officer, said, “Telix will feature in four presentations at this year’s ASCO GU, which showcase the depth and differentiation of our therapeutic urologic pipeline, ...

Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community ...

Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium. The Dana-Farber led research exemplifies innovative and ...

Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...

A recent meta-analysis shows that acute toxicities following radiation therapy signal a greater risk for later complications in patients with prostate cancer.